The next steps for TGR-1202 and targeting the gene c-Myc

The next steps for TGR-1202 and targeting the gene c-Myc

VJHemOnc

3 years
437 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Owen A O'Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, discusses the next steps for studying TGR-1202, which is a novel, next generation PI3K-delta inhibitor with promising activity in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). He also talks about findings concerning the targeting of oncogenes such as c-Myc in aggressive lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
1 Views
Cancer-News 1 hour
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
23 Views
Cancer-News 1 day
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 1 day
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
9 Views
kidneycancer 1 day
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 1 day
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 2 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 2 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
9 Views
kidneycancer 2 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 3 days